Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0HJ5H
|
||||
| Former ID |
DIB007684
|
||||
| Drug Name |
BGC-20-1531
|
||||
| Synonyms |
AH-22921; EP4 antagonist, BTG; EP4 antagonist, Pharmagene; Migraine therapy, BTG; Migraine therapy, Pharmagene; PGN-1531; EP4 receptor antagonists (migraine), Asterand; R-4 (migraine), Pharmagene
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Pharmagene plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H28N2O6S
|
||||
| InChI |
InChI=1S/C26H28N2O6S/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23/h4-13,15,18,20,24H,14,16H2,1-3H3,(H,28,29)
|
||||
| InChIKey |
BGXAOTTWXYPIQN-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 74480-23-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2 receptor, EP4 subtype | Target Info | Antagonist | [544082] | |
| References | |||||
| Ref 522648 | ClinicalTrials.gov (NCT00888680) Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine. U.S. National Institutes of Health. | ||||
| Ref 540329 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3380). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.